摘要
目的:探讨布拉氏酵母菌联合序贯疗法根除儿童幽门螺杆菌(Hp)感染的疗效。方法:选取2020年1月~2022年6月期间佛山市妇幼保健院就诊的Hp感染患儿100例,均进行胃镜下胃黏膜病变程度评分。按照随机数字表法将患儿分为观察组(n=50,序贯疗法联合布拉氏酵母菌)和对照组(n=50,序贯疗法),均治疗10 d。比较两组治疗前、治疗10 d后免疫功能相关指标、炎症因子指标以及不良反应发生率,并比较治疗后4周的Hp根除率以及治疗前、治疗后4周的胃黏膜病变程度评分。结果:观察组的临床总有效率、Hp根除率高于对照组,胃黏膜病变程度评分优于对照组(P<0.05)。治疗10 d后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)升高,且观察组高于对照组,CD8^(+)降低,且观察组低于对照组(P<0.05)。治疗10 d后,两组白细胞介素(IL)-10升高,且观察组高于对照组,IL-6、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)降低,且观察组低于对照组(P<0.05)。两组不良反应发生率对比无差异(P>0.05)。结论:序贯疗法联合布拉氏酵母菌用于根除儿童Hp感染治疗,可减轻胃黏膜病变程度,改善患儿的免疫功能和炎症因子水平,提高Hp根除率。
Objective:To explore the efficacy of Saccharomyces boulardii and sequential therapy to eradicate Helicobacter pylori(Hp)infection in children.Methods:100 children with Hp infection who visited Foshan Maternal and Child Health Hospital from January 2020 to June 2022 were selected,and the pathological changes of gastric mucosa were scored under gastroscope.According to the random number table method,the children were divided into an observation group(n=50,sequential therapy combined with Saccharomyces boulardii)and a control group(n=50,sequential therapy),both treated for 10 days.Immune function related indicators,inflammatory factor indicators,and incidence of adverse reactions in the two groups before treatment and 10 d after treatment were compared,the eradication rate of Hp 4 weeks after treatment and the lesion degree score of gastric mucosa before and 4 weeks after treatment were compared.Results:The total clinical effective rate and Hp eradication rate of the observation group were higher than those of the control group,and the gastric mucosa lesion degree score was better than that of the control group(P<0.05).10 d after treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)increased in both groups,and the observation group was higher than that of the control group,while CD8^(+)decreased,and the observation group was lower than that of the control group(P<0.05).10 d after treatment,the levels of interleukin-10(IL-10)in both groups increased,and the observation group was higher than that of the control group.IL-6 and tumor necrosis factor-α(TNF-α),interferon-γ(IFN-γ)decreased,and the observation group was lower than that of the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Sequential therapy combined with Saccharomyces boulardii for the eradication of Hp infection in children can reduce the degree of pathological changes in gastric mucosa,improve the immune function and inflammatory factor level of children,and increase the eradication rate of Hp.
作者
罗威耀
黄为民
万瑞平
何昀
伍咏瑶
徐艳军
杨帆
LUO Wei-yao;HUANG Wei-min;WAN Rui-ping;HE Yun;WU Yong-yao;XU Yan-jun;YANG Fan(Department of Neonatology,The First Clinical Medical College of Southern Medical University(Southern Hospital),Guangzhou,Guangdong,510515,China;Department of Pediatrics,FoshanMaternal and Child Health Hospital,Foshan,Guangdong,528000,China)
出处
《现代生物医学进展》
CAS
2023年第17期3237-3241,共5页
Progress in Modern Biomedicine
基金
广东省基础与应用基础研究基金项目-区域联合基金-青年基金项目(2020A1515110095)。
关键词
序贯疗法
布拉氏酵母菌
儿童
幽门螺杆菌
疗效
Sequential therapy
Saccharomyces boulardii
Children
Helicobacter pylori
Curative effect
